** Shares of Amplia Therapeutics ATX.AX rise as much as 16.3% to A$0.100, posting their biggest percentage gain since Oct. 10
** Stock hits its highest level since Nov. 15
** Drug developer reports positive clinical trial results for its pancreatic cancer drug narmafotinib
** Says 35% patients show partial response in trial vs 23% in historical standard-of-care treatment
** About 6.4 mln shares change hands, compared with the 30-day average volume of around 1.6 mln
** Stock up 20.7% YTD, including session's move
(Reporting by Aaditya Govind Rao in Bengaluru)
((Aaditya.govindrao@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.